Selank
What to know about Selank
Selank is a synthetic tuftsin-related heptapeptide developed in Russia. Human publications are small, mostly Russian-language comparisons rather than modern placebo-controlled programs.
- How it may work
- Proposed actions involve GABAergic signalling, neurotrophic pathways, and immune modulation, but the human relevance of these mechanisms remains unsettled.
- What research found
- One randomized 62-person study compared Selank with medazepam rather than placebo; a later 60-person study used phenazepam as the comparator. Independent replication is limited.
- What is not settled
- Small short studies cannot establish rare or long-term effects. FDA flags limited safety information plus immune-reaction and peptide-impurity concerns.
- Research and product status
- Selank has no licensed U.S. product. The published record is not strong enough for confident broad outcome claims.
Research reference
- Research amount range
- 250–500 mcg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Intranasal in the cited evidence; formulation matters.
- Model accumulation timescale
- ~3 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Small comparator studies reported symptom measures during short research courses, but they do not establish a dependable personal onset for anxiety, mood, sleep, or cognition.
- When to assess
- The evidence base is too small and methodologically limited to define a reliable reassessment day. Subjective calm after one use cannot establish a lasting outcome.
- Conditions and limitations
- No strong evidence establishes a required time of day, fasting state, cycle pattern, or pairing with Semax. Route and formulation in published work must match any comparison.
- When to stop
- No validated target, maintenance pattern, or quit rule exists for general use. Worsening mood, a severe reaction, or a new concerning symptom warrants stopping and prompt review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about Selank alongside other compounds or medicines.
Key properties
- Formula
- C33H57N11O9
- Mol. weight
- 751.9 Da
- CAS
- 129954-34-3
- PubChem CID
- 11765600
Sequence (one-letter)
TKPRPGP
External references
Degrades fast in plasma; estimates are rough.
Used intranasally where it is licensed; no Western dose-ranging trial fixes an injected schedule, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Russian Selank anxiolytic literaturePreclinical and small clinical studies, largely Russian-language.